



Eureka!

Laboratory Aha Moments

Misty Huddleson, MLS(ASCP)^{cm}
Immunohematology Reference Laboratory Technologist II

Learning Objectives

After participating in this course, you will be able to:


- recognize the unpredictable nature of antibody identification
- evaluate patient information for clues to antibody identification
- analyze initial serologic blood bank test results to make an educated prediction for the cause of antibody reactivity in a patient sample
- select further testing techniques to prove or disprove a suspected cause of reactivity in a serologic blood bank investigation

Antibody Identification Clues Patient Information



- Age, gender, race
- Pregnancy and transfusion history
- Medications and diagnosis
- Initial testing

Antibody Identification Clues Initial Test Results




- ABO/Rh type
- Patient Phenotype
- DAT
- Antibody screen/initial panel

Antibody Identification Clues Additional Tests



Antibody Identification - The Usual Suspects

- ABO Discrepancy
 - ABO subgroup
 - Cold reactive antibodies
- Positive DAT
 - Alloantibody formation
 - Drug related
 - Autoantibody
- Panel with positive and negative reactions
 - Single or simple multiple alloantibodies
- Panel with all cells positive
 - Autoantibody
 - Drug related/reagent dependent antibody



Initial IRL Testing:

When a sample is referred to the Immunohematology Reference Laboratory we already know it is a problem!

Initial IRL testing includes:

- ABO using anti-A, anti-B, anti-A,B, and A₁, A₂, and B cells
- Rh type using anti-D including weak D testing
- Rh phenotype testing the patient for C, E, c, and e
- DAT is performed using polyspecific antihuman globulin
 - If positive, we will test with Anti-IgG and anti-C3
- A reagent red cell panel and auto control in tube at IS and PEG/IAT
 - Testing in other methods such as LISS, enzymes, or Gel is usually part of the follow up testing

Case Study #1 Patient Information

- Age: 57
- Medications: Not Provided
- Gender: Female
- Race: Unknown
- Diagnosis: AMS, Fever
- Pregnancy History: Not Provided
- Transfusion History: Within the last 3 months
- Referring Facility's Results: Not Provided

Case Study #1 Initial Testing

ABO/Rh								
Cell Typing						Serum Grouping		
	A	B	A,B	D	Control	A1	A2	B
IS	0	4+	3+	4+	0	3+	2+	0

DAT				
	Poly	IgG	C3	Control
IS	w+	m+		0
5' RT	1+		1+	0



Case Study #1 Initial Testing

	D	C	E	c	e	f	C ^o	M	N	S	s	P1	Le ^a	Le ^b	Lu ^a	Lu ^b	K	k	Fy ^a	Fy ^b	Jk ^a	Jk ^b	IS	PEG IAT	
1	0	0	0	+	+	+	0	+	+	+	0	0	0	+	0	+	0	+	+	0	0	+	0	2+	
2	0	0	0	+	+	+	0	+	+	+	+	0	+	0	0	+	+	+	+	+	+	+	+	0	2+
3	0	+	0	+	+	+	0	+	+	0	+	W	0	+	0	+	0	+	0	+	+	+	0	2+	
4	0	0	+	+	+	+	0	0	+	0	+	+	0	+	0	+	0	+	0	+	0	+	0	2+	
5	0	0	0	+	+	+	0	+	+	0	+	W	+	0	0	+	0	+	+	+	+	0	0	2+	
6	+	0	0	+	+	+	0	0	+	+	+	+	+	0	0	+	0	+	0	0	+	+	0	2+	
7	+	+	0	0	+		0	+	0	+	0	W	+	0	+	+	0	+	0	+	0	+	0	2+	
8	+	+	0	0	+		0	+	0	0	+	W	0	+	0	+	+	+	0	+	0	+	0	2+	
9	+	+	0	0	+		+	+	+	0	+	0	0	+	0	+	0	+	+	0	+	0	0	2+	
10	+	0	+	+	0		0	+	+	0	+	+	0	0	0	+	0	+	0	+	0	+	0	2+	
11	+	+	+	0	+		0	+	+	0	+	+	0	+	0	+	0	+	+	+	0	+	0	2+	
Auto																							0	2+	



Case Study #1


The Clues

What we learned from patient information and initial testing:



Case Study #1

The Clues



Clue

- DAT is positive for both IgG and C3

Prediction

- IgG antibodies are coating the red blood cells


Additional Testing

- Perform an elution



Case Study #1

The Clues



Clue

- Antibody panel is positive with all cells, including auto control

Prediction


- Positive auto control reacting at same strength as all panel cells indicates a potential warm autoantibody

Additional Testing

- Due to recent transfusion, perform alloadsorption.

Case Study #1

The Clues



Clue

- Patient has been transfused within the last 3 months.

Prediction

- Patient has potential to produce alloantibodies and transfused cells are probably still present in the patient's circulation.

Additional Testing

- Cell separation will be required prior to antigen typing.

Case Study #1

Course of Action

Hypothesis: Patient has a warm autoantibody.

Additional Testing:


- cell separation to confirm if the plasma antibody is allo or auto
- cell separation to perform full phenotype
- alloadsorption to rule out underlying alloantibodies
- elution
 - Due to limited sample, the transfused cell population from the microhematocrit cell separation was retained for the elution.

Case Study #1

Elution

	D	C	E	e	e	f	C ^w	M	N	S	s	P ₁	Le ^a	Le ^b	Lu ^a	Lu ^b	K	k	Fy ^a	Fy ^b	Jk ^a	Jk ^b	Eluate	Last Wash
I	+	+	o	o	+		o	+	o	o	+	W	o	+	o	+	o	+	o	+	o	+	1+	0✓
II	+	o	+	+	o		o	o	+	+	+	W	o	+	o	+	+	+	+	o	+	+	1+	0✓
III	o	o	o	+	+	+	o	+	+	+	o	+	+	o	o	+	o	+	+	+	+	o	1+	0✓

Case Study #1 Allogeneic Adsorptions



Allogeneic Adsorption Applications

- Resolution of reactivity due to autoantibody
- Confirmation of a weak subgroup or antigen via adsorption/elution
- Removal of a high prevalence antibody to allow for antibody exclusion
- Separation of multiple antibody specificities
- Removal of certain interfering therapeutic substances

Case Study #1 Adsorbed Plasma Testing

	D	C	E	e	e	M	N	S	s	P1	Le ^a	Le ^b	K	k	Fy ^a	Fy ^b	Jk ^a	Jk ^b	F1
R1R1	+	+	o	o	+	+	o	+	o	+	o	o	o		o	+	+	o	
R2R2	+	o	+	+	o	o	+	o	+	+	o	+	o		+	o	+	+	
rr	o	o	o	+	+	+	o	+	o	+	o	+	o		+	o	o	+	
R1R1																			
1	+	o	+	+	o	o	+	o	+	+	+	o	o		+	+	+	+	0✓
2	+	+	o	o	+	+	o	+	+	o	o	+	o		+	o	+	o	0✓
3	+	o	+	+	o	+	o	+	+	+	o	+	+	o	o	+	o	+	0✓
R2R2																			
1	+	+	o	o	+	+	o	+	o	+	o	+	+	+	o	+	+	o	0✓
2	+	o	+	+	o	+	+	+	+	+	+	o	o		+	+	+	+	0✓
rr																			
1	+	+	o	o	+	o	+	o	+	+	+	o	o		o	+	o	+	0✓
2	+	o	+	+	o	o	+	+	+	o	o	+	o		+	+	+	o	0✓
3	+	+	o	o	+	+	o	o	+	o	o	o	+	o	+	+	+	+	0✓


Identification of Warm Autoantibody Reactivity

- At least one of the following:
 - Auto Control Reactive at 37C and/or AHG
 - DAT is positive
- Serum studies are reactive at 37C and/or AHG.
- At least one of the following:
 - Neat serum reacts with DAT-negative autologous red blood cells.
 - Adsorption with autologous red blood cells removes autoantibody reactivity

Case Study #1 Autoantibody Confirmation

Neat plasma tested
against DAT negative
harvested reticulocytes

	Peg/IgG
Auto	0✓



Case Study #1

Phenotype

Testing performed on reticulocytes harvested by microhematocrit centrifugation.

DAT	
	IgG
IS	0✓

C	E	c	e	K	Fya	Fyb	Jka	Jkb	M	N	S	s	P1	Lea	Leb
0	0	4+	4+	0	0	0	3+	0	0	2+	0	0	3+	0	0

Case Study #1

The Clues

What we learned from additional testing:

Case Study #1

The Clues



Patient's phenotype:

S	s
0	0

Could the patient have an anti-U???

Case Study #1

Additional testing

	D	C	E	c	e	f	C ^w	M	N	S	s	Pi	Le ^a	Le ^b	Lu ^a	Lu ^b	K	k	Fy ^a	Fy ^b	Jk ^a	Jk ^b	PEG IAT	Eluate	Test Wash		
1	+	0	0	+	+		0	+	0	0	0	W	0	+	0	+	0	+	0	0	+	0	0	0	0	0	0
2	+	0	0	+	+		0	+	+	0	0	0	0	0	0	+	0	+	+	0	+	+	0	0	0	0	0
3	0	0	0	+	+	+	0	+	+	0	0	+	+	0	0	+	0	+	0	0	+	0	0	0	0	0	0

Testing with S-s-U- reagent red cells was nonreactive, confirming the presence of anti-U in both the serum and eluate

Case Study #1

Conclusion and Follow Up

Antibody confirmed as anti-U in serum and eluate

Additional follow up:

- Molecular testing to confirm if the patient is a true U- or Uvar
- Source U- compatible blood for transfusion
- The patient successfully received 2 units of U- RBCs and was discharged

This case demonstrated the complexity of identifying a high prevalence antibody when both the serum and eluate contain broad reactivity

Case Study #2

Patient Information

- Age: 60
- Medications: Not Provided
- Gender: Female
- Race: White
- Diagnosis: Sepsis/UTI
- Pregnancy History: None
- Transfusion History: Four units in the previous week
- Referring Facility's Results: History of anti-Fy^a

Case Study #2 Initial Testing

ABO/Rh								
Cell Typing						Serum Grouping		
	A	B	A,B	D	Control	A1	A2	B
IS	4+	0	4+	4+	0	0	0	3+

DAT				
	Poly	IgG	C3	Control
IS	1+	1+		0
5' RT	0		o✓	0



Case Study #2 Initial Testing

	D	C	E	c	e	f	C ^o	M	N	S	s	P1	Le ^a	Le ^b	Lu ^a	Lu ^b	K	k	Fy ^a	Fy ^b	Jk ^a	Jk ^b	IS	PEG IAT
1	0	0	0	+	+	+	0	+	+	+	0	0	0	+	0	+	0	+	0	0	0	+	0	2+
2	0	0	0	+	+	+	0	+	+	+	+	0	+	0	0	+	+	+	0	+	+	+	0	2+
3	0	+	0	+	+	+	0	+	+	0	+	W	0	+	0	+	0	+	0	+	+	+	0	2+
4	0	0	+	+	+	+	0	0	+	0	+	+	0	+	0	+	0	+	0	+	0	+	0	2+
5	0	0	0	+	+	+	0	+	+	0	+	W	+	0	0	+	0	+	0	+	+	0	0	2+
6	+	0	0	+	+	+	0	0	+	+	+	+	+	0	0	+	0	+	0	0	+	+	0	2+
7	+	+	0	0	+		0	+	0	+	0	W	+	0	+	+	0	+	0	+	0	+	0	2+
8	+	+	0	0	+		0	+	0	0	+	W	0	+	0	+	+	+	0	+	0	+	0	2+
9	+	+	0	0	+		+	+	+	0	+	0	0	+	0	+	0	+	0	0	+	0	0	o✓
10	+	0	+	+	0		0	+	+	0	+	+	0	0	0	+	0	+	0	+	0	+	0	2+
11	+	+	+	0	+		0	+	+	0	+	+	0	+	0	+	0	+	0	+	0	+	0	2+
Auto																							0	2+



Case Study #2

Phenotype

Testing performed on reticulocytes harvested by microhematocrit centrifugation.

DAT	
	IgG
IS	W+

C	E	c	e
3+	3+	1+ ^{mf}	3+


Case Study #2

The Clues

What we learned from patient information and initial testing:

Case Study #2

The Clues



Clue

- DAT is positive for IgG

Prediction


- IgG antibodies are coating the red blood cells, patient has multiple recent transfusions

Additional Testing

- Perform an elution

Case Study #2

The Clues



Clue

- Antibody panel is positive with all but one cell, including auto control

Prediction

- This could be a case of multiple alloantibodies

Additional Testing

- Additional selected cells are indicated as phenotype is unavailable at this time

Case Study #2 Eluate Testing

	D	C	E	e	e	f	C ^w	M	N	S	s	P1	Le ^a	Le ^b	Lu ^a	Lu ^b	K	k	Fy ^a	Fy ^b	Jk ^a	Jk ^b	IS	PEG IAT
1	0	0	0	+	+	+	0	+	+	+	0	0	0	+	0	+	0	+	+	0	0	+	0	2+
2	0	0	0	+	+	+	0	+	0	+	0	0	+	0	0	+	+	0	+	+	0	0	0	o✓
3	0	+	0	+	+	+	0	+	+	0	+	W	0	+	0	+	0	+	0	+	+	+	0	2+
4	0	0	+	+	+	+	0	0	+	0	+	+	0	+	0	+	0	+	+	+	0	+	0	2+
5	0	0	0	+	+	+	0	+	+	0	+	W	+	0	0	+	0	+	+	+	+	0	0	o✓
6	+	0	0	+	+	+	0	0	+	+	+	+	+	0	0	+	0	+	0	0	+	+	0	2+
7	+	+	0	0	+		0	+	0	+	0	W	+	0	+	+	0	+	+	+	0	+	0	2+
8	+	+	0	0	+		0	+	0	0	+	W	0	+	0	+	+	+	+	0	+	0	+	2+
9	+	+	0	0	+		+	+	+	0	+	0	0	+	0	+	0	+	0	0	+	0	0	o✓
10	+	0	+	+	0		0	0	+	0	+	+	0	0	0	+	0	+	+	0	+	0	0	o✓
11	+	+	+	0	+		0	+	+	0	+	+	0	+	0	+	0	+	0	+	0	+	0	2+
Auto																							0	2+





Case Study #2 Initial Testing

	D	C	E	e	e	f	C ^w	M	N	S	s	P1	Le ^a	Le ^b	Lu ^a	Lu ^b	K	k	Fy ^a	Fy ^b	Jk ^a	Jk ^b	IS	PEG IAT
1	0	0	0	+	+	+	0	+	+	+	0	0	0	+	0	+	0	+	0	0	0	+	0	2+
2	0	0	0	+	+	+	0	+	+	+	+	0	+	0	0	+	+	+	0	+	+	+	0	2+
3	0	+	0	+	+	+	0	+	+	0	+	W	0	+	0	+	0	+	0	+	+	+	0	2+
4	0	0	+	+	+	+	0	0	+	0	+	+	0	+	0	+	0	+	0	+	0	+	0	2+
5	0	0	0	+	+	+	0	+	+	0	+	W	+	0	0	+	0	+	0	+	+	0	0	2+
6	+	0	0	+	+	0	0	0	+	+	+	+	+	0	0	+	0	+	0	0	+	+	0	2+
7	+	+	0	0	+		0	+	0	+	0	W	+	0	+	+	0	+	0	+	0	+	0	2+
8	+	+	0	0	+		0	+	0	0	+	W	0	+	0	+	+	+	0	+	0	+	0	2+
9	+	+	0	0	+		+	+	+	0	+	0	0	+	0	+	0	+	0	0	+	0	0	o✓
10	+	0	+	+	0		0	+	+	0	+	+	0	0	0	+	0	+	0	+	0	+	0	2+
11	+	+	+	0	+		0	+	+	0	+	+	0	+	0	+	0	+	0	+	0	+	0	2+
Auto																							0	2+



Case Study #2

The Clues



Case Study #2

Testing Fy(a-), Jk(b-) RBCs

	D	C	E	e	e	f	C ^w	M	N	S	s	P1	Le ^a	Le ^b	Lu ^a	Lu ^b	K	k	Fy ^a	Fy ^b	Jk ^a	Jk ^b	IS	PEG IAT
1	0	0	0	+	+	+	0	+	+	+	0	0	0	+	0	+	0	+	0	0	+	0	0	2+
2	0	0	0	+	+	+	0	+	+	+	+	0	+	0	0	+	+	+	0	+	+	0	0	2+
3	+	+	0	0	+	0	0	+	0	0	+	W	0	+	0	+	0	+	0	+	+	0	0	o✓
4	+	+	0	0	+	0	0	0	+	0	+	+	0	+	0	+	0	+	0	+	+	0	0	o✓
5	+	+	0	0	+	0	0	+	+	0	+	W	+	0	0	+	0	+	0	+	+	0	0	o✓
6	+	+	0	0	+	0	0	0	+	+	0	+	+	0	0	+	0	+	0	0	+	0	0	o✓
7	+	+	0	0	+	+	+	0	+	+	0	0	0	+	0	+	0	+	+	0	+	0	0	2+
8	+	+	0	0	+	0	0	+	+	+	+	+	0	+	0	+	0	+	+	+	+	0	0	2+

Case Study #1 Adsorbed Plasma Testing

	D	C	E	c	e	M	N	S	s	P1	Le ^a	Le ^b	K	k	Fy ^a	Fy ^b	Jk ^a	Jk ^b	F1
R1R1	+	+	o	o	+	+	o	+	o	+	o	o	o		o	+	+	o	
R2R2	+	o	+	+	o	o	+	o	+	+	o	+	o		+	o	+	+	
rr	o	o	o	+	+	+	o	+	o	+	o	+	o		+	o	o	+	
rr																			
1	+	o	+	+	o	o	+	+	+	o	o	+	o		+	+	+	o	0✓
2	+	+	o	o	+	+	o	o	+	o	o	o	+	o	+	+	+	+	0✓

In this case, we decided to adsorb with just the rr cells,
which are c+, Fy(a+) and Jk(b+) and E-, K-

Cells were tested with the adsorbed serum to rule out the
presence of anti-E and anti-K



36

Case Study #2 The Conclusion?



We have now identified anti-Jkb
in the patient's eluate and anti-c,
Fy^a, and Jk^b in the patient's
serum.

Prior to reporting our test results,
we perform a robust self-review
of testing to ensure it adheres to
standards – and we notice...



37

Case Study #2 The Conclusion?



We have not ruled out anti-f!

The f antigen is a compound antigen expressed on RBCs having c and e antigens in the same haplotype.

It is usually made by individuals with the R1R2 phenotype (C+E+c+e+)

Case Study #2 Testing Fy(a-), Jk(b-) RBCs

	D	C	E	c	e	f	C ^w	M	N	S	s	P1	Le ^a	Le ^b	Lu ^a	Lu ^b	K	k	Fy ^a	Fy ^b	Jk ^a	Jk ^b	IS	PEG IAT
1	0	0	0	+	+	+	0	+	+	+	0	0	0	+	0	+	0	+	0	0	+	0	0	2+
2	0	0	0	+	+	+	0	+	+	+	+	0	+	0	0	+	+	+	0	+	+	0	0	2+
3	+	+	0	0	+	0	0	+	0	0	+	W	0	+	0	+	0	+	0	+	+	0	0	o✓
4	+	+	0	0	+	0	0	0	+	0	+	+	0	+	0	+	0	+	0	+	+	0	0	o✓
5	+	+	0	0	+	0	0	+	+	0	+	W	+	0	0	+	0	+	0	+	+	0	0	o✓
6	+	+	0	0	+	0	0	0	+	+	0	+	0	0	+	0	+	0	0	0	+	0	0	o✓
7	+	+	0	0	+	+	+	0	+	+	0	0	0	+	0	+	0	+	+	0	+	0	0	2+
8	+	+	0	0	+	0	0	+	+	+	+	+	0	+	0	+	0	+	+	+	0	0	0	2+

Looking back at our selected cells, we notice that both of the c+ cells used to confirm anti-c are rr cells, which are f antigen positive. Let's run a few more cells...

Case Study #2

Testing f-, Fy(a-), Jk(b-) RBCs

	D	C	E	c	e	f	C ^w	M	N	S	s	P ₁	Le ^a	Le ^b	Lu ^a	Lu ^b	K	k	Fy ^a	Fy ^b	Jk ^a	Jk ^b	IS	PEG IAT	
1	+	0	+	+	0	0	0	+	+	+	0	0	0	+	0	+	0	+	0	0	+	0	0	0	o✓
2	+	0	+	+	0	0	0	+	+	+	+	0	+	0	0	+	+	+	0	+	+	0	0	0	o✓
3	+	+	0	+	+	+	0	0	+	+	+	+	0	+	0	+	0	+	0	+	+	0	0	0	2+

Some reagent manufacturers do not test for the f antigen and will leave that result blank on the manufacturer's antigen profile. However, based on the phenotype of the cell, you know whether the f antigen is present. Any cell with c and e on the same haplotype will carry the f antigen.

The adsorption with rr cells would have removed anti-f as well as the other alloantibodies present. We ran one additional f positive reagent cell with neat serum, just to confirm our identification!



40

Case Study #2

Conclusion and Follow Up

Antibodies confirmed as anti-Jk^b in the eluate and anti-f, -Fy^a, -Jk^b in the serum

Additional follow up:


- A subsequent untransfused sample was sent about six months later and the patient phenotype was confirmed as R1R2
- The patient successfully received 2 units of c-, Fy(a-), Jk(b-) RBCs and was discharged

This case demonstrated the complexity of identifying multiple alloantibodies including anti-f



41

Eureka!



Objective

- Antibody ID is unpredictable, and the laboratory uses many clues to come to a valid conclusion

Challenge

- Patient demographics and history and initial testing may point in the wrong direction

Conclusion

- Antibody identification can be challenging, rewarding, frustrating, and exhausting – and we love it!

Questions

